Clinical Cancer Research

Papers
(The H4-Index of Clinical Cancer Research is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas337
Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas234
DLK1 distinguishes subsets of NF1-associated malignant peripheral nerve sheath tumors with divergent molecular signatures225
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA219
Challenges to Innovation Arising from Current Companion Diagnostic Regulations and Suggestions for Improvements208
Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present201
Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer193
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade182
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma169
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer163
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer162
Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial158
Abstract PO-096: Blocking the CXCL12/CXCR4 pathway both radiosensitizes brain metastases in mice and protects against radiation-induced cognitive dysfunction following whole brain irradiation in rats144
Abstract IA-018: Molecular landmarks of tumor hypoxia across cancer types130
Selected Articles from This Issue123
Selected Articles from This Issue119
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study119
Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial119
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma116
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression115
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer113
Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer111
Immunotherapy of Neuroblastoma: Facts and Hopes108
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer108
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study107
Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer107
Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years106
Selected Articles from This Issue101
Selected Articles from This Issue101
Abstract PR-007: Targeting FASN improves type I interferon responses in irradiated glioblastoma100
Selected Articles from This Issue100
Selected Articles from This Issue99
Selected Articles from This Issue95
Selected Articles from This Issue93
Selected Articles from This Issue91
Selected Articles from This Issue90
Selected Articles from This Issue89
Abstract IA-010: Deciphering DNA end resection at DSBs87
Selected Articles from This Issue87
Abstract IA-024: Sirt2: A tumor suppressor or promotor?86
Abstract PO-095: Intrinsic and acquired resistance to RIG-I induced anti-tumor responses85
Abstract PO-019: Radiotherapy in cancer is associated with a deletion signature that contributes to poor patient outcomes85
Abstract PO-032: Mechanistic studies of hypoxia as a driver of genomic instability in prostate cancer84
Abstract PR-006: Pulsed low-dose-rate radiation (PLDR) limits pancreatic pro-tumor stroma aggravation: Pre-clinical basis for an ongoing PLDR trail83
Abstract IA-003: Oxygen dependent resistance to PARP inhibitors83
Abstract PO-018: Hypoxia activated prodrugs of DNA-dependent protein kinase inhibitors as radiosensitisers of head and neck squamous cell carcinomas81
Abstract IA-012: Differential immunological effects of carbon-ion versus photon radiation therapy81
Abstract IA-021: Predicting radiotherapy outcomes: Radiogenomics and risk of radiotherapy toxicity80
Abstract PO-044: Exploiting a radiotherapy induced immunologic double bind in advanced prostate cancer79
Abstract PO-053: Targeting focal adhesions to limit radiation-induced glioblastoma cell invasion79
Abstract PO-035: Understanding the role of hypoxia and PTEN loss in driving prostate cancer progression79
Abstract PO-097: Selective targeting and imaging of orthotopic glioblastoma after a single systemic dose of a novel hydoxyl dendrimer radionuclide79
Abstract PR-005: Adenosine signaling and radiation-induced immunosuppressive changes to the tumor microenvironment79
Abstract PR-008: Identification and characterization of the molecular mechanisms of SCLC chemo-radiation resistance78
Abstract PO-100: Theragnostic tumor-targeted manganese dioxide-loaded polymer-lipid nanoparticles for magnetic resonance image-guided radiation therapy77
Selected Articles from This Issue77
Abstract IA-017: Chromatin and gene transcription in hypoxia76
Selected Articles from This Issue76
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer76
Selected Articles from This Issue76
Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial75
Immunogenomic Landscape of Neuroendocrine Prostate Cancer74
NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy73
Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors73
Correction: Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer73
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers72
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial72
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study72
Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study71
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy71
Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer71
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide71
0.17939496040344